BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
CYP17-IN-1 is an effective cell metabolism inhibitor, that has the ability to prevent the pathway of metabolism by inhibiting cytochrome P450.
Molecular Weight
312.4
Molecular Formula
C18H17FN2S
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Applications
CYP17-IN-1 is a metabolism inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of hormone-sensitive cancers, such as prostate cancer, by reducing androgen levels.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.